Innofactor’s Q1 results were good and beat our expectations.
Redeye adjusts our growth assumptions slightly for 2023e and beyond.
Redeye sees good opportunities for Impact Coatings to execute on its growth plan.
Scanfil reported a very good Q1, and the outlook has improved for the remainder of this year.
Ahead of Relais Q1, due on 4 May, we maintain our estimates intact.
Slow start to '23, but March better, 4m-5m EE milestones delayed -14% y-o-y EBIT drop caused by temp...
Weakness for nurses segment in Sweden... ...more than offset by other regions/segments A strong star...
Redeye returns with a research update following the Q1 report.
Redeye comments on BioInvent's first quarter report of 2023.
Sales +6% y-o-y, -3% vs. ABGSCe 6% EBIT margin (3% in Q1'22), supported by slowdown in opex Cons.
Clean EBIT SEK 149m vs. ABGSCe 90m New investments in CTMP and renewable energy Conference call at 1...
Redeye comments on SenzaGen’s Q1 2023 sales update, where sales during the first quarter amounted to...
Prispressen borde normaliseras när lagertömningen är bakom oss Försäljningen sjönk 65% organiskt i Q...
Storaffär i diabetesfältet I denna analysuppdatering lyfter vi fram en affär som nyligen gjorts i di...
Inleder 2023 starkt Trots ökad oro kring den allmänna ekonomin fortsätter CAG att visa hög tillväxt ...
Förvärv indikerar riktningen framåt VO2 har meddelat förväven av Locads och Madington.
EBIT SEK 6.5m (-43% vs. ABGSCe 11.4m), dip in cup sales Somewhat disappointing EEs of 3.
Redeye comments on Alelion's Q1 report, where the gross margin was nine percentage points better tha...
Redeye was hoping for a little more in terms of sales, given the higher levels reported in the last ...
Scanfil reported 1% above our net sales forecast in Q1.
